Roche Oncology is dedicated to improving patient care by developing novel medicines for the treatment and management of different-type of cancers. Research and Development in the disease area of oncology aims to provide effective cancer therapies through the discovery and development of novel therapeutics that target the specific molecular pathways associated with cancer.

Traditionally, anti-cancer drugs have been largely non-specific, and frequently directed against general processes rather than against tumor-specific molecular targets. Although efficacious, these agents are limited, not only by low response rates but by narrow safety margins. Tumor biology is driven by an iterative process of mutation and selection that results in the acquisition of multiple novel properties by the malignant cells.

Therefore, the future of cancer therapy will rely on the choice of the most appropriate combination of drugs for patients, based on the genetic profile of their tumor. The realisation of such "personalised cancer care" through rational integration of diagnostics and therapeutics is a major focus of Roche Oncology and Diagnostics. This fitting of treatment to patients is the foundation for Personalized Healthcare (PHC) which represents a major change in our approach to healthcare.

PHC is already happening – the key enabler is a new model for research and development which uses the combined expertise of Pharma and Diagnostics throughout the value chain.

Much remains to be done to usher in the era of Personalized Healthcare. It is not easy and it will take time. In terms of the benefits to patients and the future of our industry, it is the right and the only way to move forward.

While PHC will be a long-term commitment, requiring patience and perseverance, we also need to bring a greater sense of urgency to our activities in this field.

With our expertise in diagnostics, genetics/genomics and drug discovery, Roche is uniquely positioned to continue to drive this trend in oncology and expand our leadership in the field.

This strategy of Oncology at Roche will allow the company to focus discovery efforts on areas where we can provide first-in-class small molecules or novel biologicals — to enhance development through tailored preclinical and clinical profiling.

Oncology product portfolio:

  1. Herceptin
  2. Ristova
  3. Avastin
  4. Tarceva
  5. Xeloda

Please note that Roche is unable to answer questions on individual disease treatment / management matters. These should be discussed with your doctor. As product information and availability varies from country to country, we are able to respond to Pakistan enquiries only. We cannot answer product-related questions through this website.

Following products are currently marketed by Roche Pakistan. The below information is a guide only.